Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Hartung

Showing results (21-30 of 110) with videos related to

Pageof 11
Sort By:
Neurology|February 12, 2016
Author responseDaniel M Hartung, Dennis N Bourdette, Sharia Ahmed, et al.
Neurology|January 17, 2020
Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosisDaniel M Hartung, Kirbee A Johnston, Jonah Geddes, et al.
Journal of Managed Care & Specialty Pharmacy|November 17, 2023
Economic burden of multiple sclerosis in the United States: A systematic literature reviewMarion Schauf, Harini Chinthapatla, Seema Dimri, et al.
Neurology|November 27, 2019
Qualitative study on the price of drugs for multiple sclerosis: Gaming the systemDaniel M Hartung, Lindsey Alley, Kirbee A Johnston, et al.
Clinical Therapeutics|December 4, 2014
Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communicationDaniel M Hartung, Luke Middleton, Sheila Markwardt, et al.
Annals of Internal Medicine|October 15, 2019
Older Drugs With Limited Trial Evidence: Are They Worth the Expense?Daniel M Hartung, David M Cohen, Atul Deodhar, et al.
International Journal of MS Care|April 25, 2022
Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare PopulationDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
BMC Family Practice|January 2, 2013
A pilot study evaluating alternative approaches of academic detailing in rural family practice clinicsDaniel M Hartung, Ann Hamer, Luke Middleton, et al.
Systematic Reviews|April 16, 2015
The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysisAmanda S Meeker, Megan C Herink, Dean G Haxby, et al.
Journal of Clinical Epidemiology|April 26, 2016
Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting sourceBethany Withycombe, Mac Ovenell, Amanda Meeker, et al.
Pageof 11

Showing results (21-30 of 110) with videos related to

Sort By:
Pageof 11
Neurology|February 12, 2016
Author responseDaniel M Hartung, Dennis N Bourdette, Sharia Ahmed, et al.
Neurology|January 17, 2020
Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosisDaniel M Hartung, Kirbee A Johnston, Jonah Geddes, et al.
Journal of Managed Care & Specialty Pharmacy|November 17, 2023
Economic burden of multiple sclerosis in the United States: A systematic literature reviewMarion Schauf, Harini Chinthapatla, Seema Dimri, et al.
Neurology|November 27, 2019
Qualitative study on the price of drugs for multiple sclerosis: Gaming the systemDaniel M Hartung, Lindsey Alley, Kirbee A Johnston, et al.
Clinical Therapeutics|December 4, 2014
Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communicationDaniel M Hartung, Luke Middleton, Sheila Markwardt, et al.
Annals of Internal Medicine|October 15, 2019
Older Drugs With Limited Trial Evidence: Are They Worth the Expense?Daniel M Hartung, David M Cohen, Atul Deodhar, et al.
International Journal of MS Care|April 25, 2022
Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare PopulationDaniel M Hartung, Kirbee A Johnston, Jessina C McGregor, et al.
BMC Family Practice|January 2, 2013
A pilot study evaluating alternative approaches of academic detailing in rural family practice clinicsDaniel M Hartung, Ann Hamer, Luke Middleton, et al.
Systematic Reviews|April 16, 2015
The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysisAmanda S Meeker, Megan C Herink, Dean G Haxby, et al.
Journal of Clinical Epidemiology|April 26, 2016
Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting sourceBethany Withycombe, Mac Ovenell, Amanda Meeker, et al.
Pageof 11